Breast Cancer

A recent study has found that there may be no risk of increasing skin irritation by using antiperspirants for patients with breast cancer undergoing radiation.

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer (TNBC).

A recent study found that women with breast cancer often have a network of people that they consult to help them make treatment decisions.

Breast cancer expert Joyce O'Shaughnessy, MD, discusses the current treatments for metastatic triple negative breast cancer (TNBC) as well as potential options in the future.

The FDA has approved neratinib (Nerlync) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Moving Forward Together 3 is a study evaluating how to get breast cancer survivors exercising, by using other breast cancer survivors as coaches.

According to new research, pregnancy does not increase the risk of recurrence for women who have had early breast cancer.

Clinicals can use mutiple-gene panels to identify mutations to test for breast cancer and ovarian cancer risk.

Jennifer Ligibel, MD, discusses Breast Cancer Weight Loss Study and how a weight loss intervention may help patients with breast cancer.

Researchers found that the rate of suicide in patients with lung cancer is much higher than those with other types of cancer.

A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.

Communication is key when it comes to discussing genetic information and hereditary cancers with family members.

Adjuvant pertuzumab may help some early breast cancer patients.

The PARP inhibitor olaparib (Lynparza) was shown to reduce the risk of disease progression by 42% compared to standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer.

A recent study presented at the 2017 ASCO Annual Meeting found that breast cancer survivors who became pregnant had no greater risk of recurrence or death than women who underwent breast cancer treatment but did not become pregnant.

As presented at the 2017 ASCO Annual Meeting, adding abemaciclib to fulvestrant can reduce the risk of disease progression or death by 45% compared to fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer.

According to findings presented at 2017 ASCO, frontline treatment with ribociclib (Kisqali) plus letrozole improved PFS for patients with HR+/HER2- advanced breast cancer.

The traditional Chinese exercise, tai chi, may assist breast cancer survivors experiencing insomnia.

A form of T-cell (non-Hodgkin) lymphoma known as breast implant associated anaplastic large-cell lymphoma (BIA-ALCL) has been noted as a rare association with the implant-based approach of reconstructive surgery post mastectomy.

Recent changes to FDA labels regarding adverse events.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

Researchers found that tai chi chih, including guided movement and meditation, may be helpful in reducing insomnia experienced by breast cancer survivors.

Examining the experience of 3 women, aged 24 to 28, with stage III breast cancer, oncology nurses from the University of Texas at Austin School of Nursing aimed to gain more insight into the experience of younger woman with breast cancer.

Patricia Jakel, RN, MN, AOCN, ended up on the opposite of the bed than she was used to when she was diagnosed with stage III invasive lobular breast cancer.

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.